These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 380614)

  • 1. Clofibrate and diabetes control in patients treated with oral hypoglycaemic agents.
    Daubresse JC; Daigneux D; Bruwier M; Luyckx A; Lefebvre PJ
    Br J Clin Pharmacol; 1979 Jun; 7(6):599-603. PubMed ID: 380614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin and clofibrate in maturity onset diabetes mellitus: advantages of combined treatment.
    De Silva SR; Betteridge DJ; Shawe JE; Cudworth AG; Alberti KG
    Diabete Metab; 1979 Sep; 5(3):223-9. PubMed ID: 574098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of short-term clofibrate on glucose metabolism and insulin secretion in patients with mild maturity-onset diabetes mellitus.
    Ferrari C; Romussi M; Bertazzoni A; Testori GP; Grimaldi MG
    Biomedicine; 1978 Jun; 29(4):133-6. PubMed ID: 556385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of clofibrate on plasma glucose, lipoproteins, fibrinogen, and other biochemical and haematological variables in patients with mature onset diabetes mellitus.
    Calvert GD; Blight L; Franklin J; Oliver J; Wise P; Gallus AS
    Eur J Clin Pharmacol; 1980 May; 17(5):355-62. PubMed ID: 6998709
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of clofibrate on glucose tolerance in maturity onset diabetes.
    Barnett D; Craig JG; Robinson DS; Rogers MP
    Br J Clin Pharmacol; 1977 Aug; 4(4):455-8. PubMed ID: 901737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Regadrin treatment of diabetes mellitus].
    Hohlfeld R; Neugebauer A; Haaser B; Marek H; Reuter W
    Z Gesamte Inn Med; 1973 May; 28(10):Suppl 10:154-6. PubMed ID: 4734038
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia.
    Krut LH; Seftel HC; Joffe BI
    S Afr Med J; 1977 Mar; 51(11):348-52. PubMed ID: 323994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Lipid-lowering effect of bezafibrate in patients with diabetes mellitus and hyperlipidaemia (author's transl)].
    Wahl P; Hasslacher C; Lang PD; Vollmar J
    Dtsch Med Wochenschr; 1978 Aug; 103(31):1233-7. PubMed ID: 668570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clofibrate in insulin-dependent diabetes.
    Twomey C; Bloom A
    Ir J Med Sci; 1979 Feb; 148(2):31-5. PubMed ID: 478810
    [No Abstract]   [Full Text] [Related]  

  • 10. Improvement of glucose tolerance in NIDDM by clofibrate. Randomized double-blind study.
    Kobayashi M; Shigeta Y; Hirata Y; Omori Y; Sakamoto N; Nambu S; Baba S
    Diabetes Care; 1988 Jun; 11(6):495-9. PubMed ID: 3042317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The influence of clofibrate on elevated serum lactate levels in diabetic patients treated with biguanides (author's transl)].
    Vogelberg KH; Cicmir I; Heggen ME
    Arzneimittelforschung; 1980; 30(4):683-5. PubMed ID: 7190412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intensified therapy of newly detected maturity onset diabetes].
    Pissarek D; Panzram G; Lundershausen R; Adolph W; Senf L
    Endokrinologie; 1980 Jan; 75(1):105-15. PubMed ID: 6989592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood glucose variations and clinical experience with glibenclamide in diabetes mellitus.
    O'Sullivan DJ; Cashman WF
    Br Med J; 1970 Jun; 2(5709):572-4. PubMed ID: 5526612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of clofibrate on glucose tolerance, insulin secretion, triglycerides and fibrinogen in patients with coronary heart disease.
    Enger SC; Johnsen V; Samuelsen A; Laws EA
    Acta Med Scand; 1977; 201(6):563-6. PubMed ID: 327758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The question of adverse effects of clofibrate. Experience in patients with diabetes mellitus].
    Häser C; Rahlfs V; Mehnert H
    Ther Ggw; 1976 Aug; 115(8):1382-95. PubMed ID: 793084
    [No Abstract]   [Full Text] [Related]  

  • 16. Blood glucose concentrations and glycosuria during and after one year of acarbose therapy.
    Aubell R; Boehme K; Berchtold P
    Arzneimittelforschung; 1983; 33(9):1314-8. PubMed ID: 6357206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians.
    Research Committee of the Scottish Society of Physicians
    Br Med J; 1971 Dec; 4(5790):775-84. PubMed ID: 4943606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clofibrate enhances the affinity of insulin receptors in non-insulin dependent diabetes mellitus.
    Murakami K; Nambu S; Koh H; Kobayashi M; Shigeta Y
    Br J Clin Pharmacol; 1984 Jan; 17(1):89-91. PubMed ID: 6362704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin and oral hypoglycaemic agents. II. Clinical and therapeutic aspects.
    Breidahl HD; Ennis GC; Martin FI; Stawell JR; Taft P
    Drugs; 1972; 3(3):204-26. PubMed ID: 4561637
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.